Synaffix BV

2:00 PM - 2:15 PM (PDT), Tuesday, June 14, 2022
Synaffix BV is a biotech company that has established a proprietary, clinical-stage technology platform that enables best-in-class antibody-drug conjugates (ADCs) in terms of safety and efficacy.

Our technology out-licensing business has already translated into 3 clinical-stage ADCs, at least 15 distinct ADC programs being developed across our 9 partners and well over $3Bn in total potential value from our out-licensing deals.

Our partners include top-tier biotech and pharma companies such as ADC Therapeutics, Mersana Therapeutics, Janssen, Shanghai Miracogen, Innovent Biologics, ProfoundBio, Kyowa Kirin, Genmab and Macrogenics.

We regularly engage in discovery research collaborations with companies where Synaffix offers a consolidated ADC platform technology that enables any company with an antibody to develop a proprietary, best-in-class ADC.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
Netherlands
Year Founded:
2010
Main Therapeutic Focus:
Lead Product in Development:
N/A
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
photo
VP ,Business Development
Synaffix BV